Nanite

Executive Summary

Nanite is a preclinical-stage biotechnology company pioneering non-viral gene therapy delivery by combining AI-driven polymer design with high-throughput synthesis and in vivo screening. The company develops tissue-specific polymer nanoparticles (PNPs) that aim to overcome the key delivery hurdle limiting gene therapies, offering a safer, resorbable alternative to viral vectors. Founded in 2019 and headquartered in Cambridge, Massachusetts, Nanite’s platform uniquely integrates machine learning to optimize polymer chemistry for targeted delivery to specific tissues. While still in early development, the company’s approach addresses a critical bottleneck in the gene therapy field, potentially enabling new therapeutic modalities. Given its innovative platform and focus on a high-value problem, Nanite represents an attractive opportunity for investors seeking exposure to next-generation drug delivery technologies. However, as a private, pre-revenue company, it carries significant execution and scientific risk.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round70% success
• Q4 2026Key Preclinical In Vivo Data in Lead Indication60% success
• Q1 2027Strategic Partnership for PNP Platform40% success